JP6629321B2 - 免疫学的試薬 - Google Patents

免疫学的試薬 Download PDF

Info

Publication number
JP6629321B2
JP6629321B2 JP2017526774A JP2017526774A JP6629321B2 JP 6629321 B2 JP6629321 B2 JP 6629321B2 JP 2017526774 A JP2017526774 A JP 2017526774A JP 2017526774 A JP2017526774 A JP 2017526774A JP 6629321 B2 JP6629321 B2 JP 6629321B2
Authority
JP
Japan
Prior art keywords
antibody
cancer
antibodies
seq
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017526774A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017531028A5 (enExample
JP2017531028A (ja
Inventor
パンタレオ，ジュゼッペ
フェンウィック，クレイグ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mabquest SA
Original Assignee
Mabquest SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mabquest SA filed Critical Mabquest SA
Publication of JP2017531028A publication Critical patent/JP2017531028A/ja
Publication of JP2017531028A5 publication Critical patent/JP2017531028A5/ja
Application granted granted Critical
Publication of JP6629321B2 publication Critical patent/JP6629321B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017526774A 2014-08-05 2015-08-05 免疫学的試薬 Active JP6629321B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462033177P 2014-08-05 2014-08-05
US62/033,177 2014-08-05
US201462053366P 2014-09-22 2014-09-22
US62/053,366 2014-09-22
US201462093368P 2014-12-17 2014-12-17
US62/093,368 2014-12-17
PCT/IB2015/055943 WO2016020856A2 (en) 2014-08-05 2015-08-05 Immunological reagents

Publications (3)

Publication Number Publication Date
JP2017531028A JP2017531028A (ja) 2017-10-19
JP2017531028A5 JP2017531028A5 (enExample) 2018-09-20
JP6629321B2 true JP6629321B2 (ja) 2020-01-15

Family

ID=53836144

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017526774A Active JP6629321B2 (ja) 2014-08-05 2015-08-05 免疫学的試薬

Country Status (13)

Country Link
US (3) US9982053B2 (enExample)
EP (1) EP3177644B1 (enExample)
JP (1) JP6629321B2 (enExample)
KR (1) KR102357893B1 (enExample)
CN (1) CN107074947B (enExample)
AU (1) AU2015298356B2 (enExample)
CA (1) CA2957258C (enExample)
DK (1) DK3177644T3 (enExample)
ES (1) ES2847311T3 (enExample)
PL (1) PL3177644T3 (enExample)
PT (1) PT3177644T (enExample)
SG (1) SG11201700672YA (enExample)
WO (1) WO2016020856A2 (enExample)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−１（ｐｄ−１）に対する抗体
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
CA2957258C (en) * 2014-08-05 2023-11-07 MabQuest SA Immunological reagents
US9982052B2 (en) * 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
SG11201704283PA (en) 2014-11-26 2017-06-29 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
CA2986765A1 (en) 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
CA2991976A1 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
AU2016298227B9 (en) 2015-07-30 2019-10-31 Macrogenics, Inc. PD-1-binding molecules and methods of use thereof
EP3355920A4 (en) 2015-09-29 2019-05-15 Celgene Corporation PD-1 BINDING PROTEINS AND METHOD OF USE THEREOF
KR20250099459A (ko) 2015-11-03 2025-07-01 얀센 바이오테크 인코포레이티드 Pd-1과 특이적으로 결합하는 항체 및 그의 용도
JP6955507B2 (ja) 2015-12-14 2021-10-27 マクロジェニクス，インコーポレーテッド Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
US11214617B2 (en) * 2016-01-22 2022-01-04 MabQuest SA Immunological reagents
ES3034233T3 (en) 2016-01-22 2025-08-14 MabQuest SA Non-blocking pd1 specific antibodies
CN106008714B (zh) * 2016-05-24 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-1人源化单克隆抗体及其应用
MX389710B (es) 2016-05-27 2025-03-20 Agenus Inc Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
MA45255A (fr) * 2016-06-14 2019-04-17 Xencor Inc Anticorps inhibiteurs de points de contrôle bispécifiques
WO2018053405A1 (en) 2016-09-19 2018-03-22 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
KR102576042B1 (ko) 2016-10-11 2023-09-07 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
EP3666794A1 (en) 2016-11-01 2020-06-17 AnaptysBio, Inc. Antibodies directed against programmed death- 1 (pd-1)
RS62589B1 (sr) * 2016-11-02 2021-12-31 Jounce Therapeutics Inc Antitela na pd-1 i njihova upotreba
FI3551660T3 (fi) 2016-12-07 2023-12-11 Agenus Inc Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
CN118634323A (zh) 2016-12-07 2024-09-13 艾吉纳斯公司 抗体和其使用方法
JP7267921B2 (ja) 2017-01-06 2023-05-02 クレシェンド・バイオロジックス・リミテッド プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体
EP3565844B8 (en) 2017-01-09 2023-04-12 Tesaro, Inc. Methods of treating cancer with anti-pd-1 antibodies
AU2018207172B2 (en) 2017-01-13 2023-10-12 Mink Therapeutics, Inc. T cell receptors that bind to NY-ESO-1 and methods of use thereof
CN107474135B (zh) * 2017-02-17 2020-08-18 广西医科大学 抗PD-1的纳米抗体PD-1/Nb20及其制备方法与应用
EP3589652B1 (en) 2017-03-04 2024-12-25 Xiangtan Tenghua Bioscience Recombinant antibodies to programmed death 1 (pd-1) and uses therefor
JP7165717B2 (ja) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド 標的免疫寛容
JP7297672B2 (ja) 2017-04-13 2023-06-26 アジェナス インコーポレイテッド 抗ｃｄ１３７抗体およびその使用方法
CN106939049B (zh) * 2017-04-20 2019-10-01 苏州思坦维生物技术股份有限公司 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用
RS64576B1 (sr) 2017-05-01 2023-10-31 Agenus Inc Anti-tigit antitela i postupci njihove primene
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
CR20190550A (es) 2017-06-05 2020-04-05 Janssen Biotech Inc Anticuerpos que se unen específicamente a pd-1 y métodos de uso
JP7387585B2 (ja) 2017-09-04 2023-11-28 アジェナス インコーポレイテッド 混合系統白血病（ｍｌｌ）特異的ホスホペプチドに結合するｔ細胞受容体およびその使用方法
CN118909118A (zh) 2017-09-07 2024-11-08 奥古斯塔大学研究所公司 程序性细胞死亡蛋白1抗体
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
CA3082297A1 (en) 2017-11-13 2019-05-16 Crescendo Biologics Limited Molecules that bind to cd137 and psma
CN108218988B (zh) * 2017-11-29 2019-10-11 广西医科大学 抗PD-1的纳米抗体PD-1/Nb52及其制备方法与应用
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
TWI708787B (zh) * 2018-03-02 2020-11-01 美商美國禮來大藥廠 Pd-1促效劑抗體及其用途
BR112020019116A2 (pt) * 2018-03-22 2021-01-12 Keires Ag Proteínas de ligação, ácido nucleico, vetor, célula hospedeira, método de produção, proteína de ligação, composição farmacêutica e kit
KR20210005646A (ko) 2018-04-26 2021-01-14 아게누스 인코포레이티드 열쇼크 단백질-결합 펩티드 조성물 및 그의 이용 방법
CN108840932B (zh) * 2018-04-28 2022-03-29 中国科学院微生物研究所 一种pd-1特异性抗体及其抗肿瘤应用
CN110404066B (zh) * 2018-04-28 2022-06-17 齐鲁制药有限公司 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
AU2019288276B2 (en) 2018-06-20 2026-02-12 Incyte Corporation Anti-PD-1 antibodies and uses thereof
WO2020141199A1 (en) 2019-01-03 2020-07-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
WO2021022043A2 (en) 2019-07-30 2021-02-04 Pairwise Plants Services, Inc. Morphogenic regulators and methods of using the same
US11629190B2 (en) 2019-08-15 2023-04-18 Oregon State University Canine antibody therapeutic for treating cancer
KR102231974B1 (ko) * 2019-08-23 2021-03-25 한국과학기술원 사람의 프로그램된 세포사멸 단백질(pd-1)에 선택적으로 결합하는 신규한 폴리펩티드 및 이의 용도
KR20220053007A (ko) 2019-08-30 2022-04-28 아게누스 인코포레이티드 항-cd96 항체 및 이의 사용 방법
EP4048063A4 (en) 2019-10-23 2023-12-06 Pairwise Plants Services, Inc. Compositions and methods for rna-templated editing in plants
KR20220110739A (ko) 2019-10-30 2022-08-09 페어와이즈 플랜츠 서비시즈, 인크. 유형 v crispr-cas 염기 편집제 및 그의 사용 방법
WO2021092130A1 (en) 2019-11-05 2021-05-14 Pairwise Plants Services, Inc. Compositions and methods for rna-encoded dna-replacement of alleles
JP2023502712A (ja) 2019-11-21 2023-01-25 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 抗ｐｄ－１／ｉｌ－１５免疫サイトカインによる新しいｐｄ－１標的免疫療法
US11976278B2 (en) 2019-12-06 2024-05-07 Pairwise Plants Services, Inc. Recruitment methods and compounds, compositions and systems for recruitment
AU2021212189A1 (en) 2020-01-30 2022-08-04 Pairwise Plants Services, Inc. Compositions, systems, and methods for base diversification
UY39058A (es) 2020-01-31 2021-08-31 Pairwise Plants Services Inc Suppresión de la respuesta de evasión a la sombra en plantas
US20230063560A1 (en) 2020-02-04 2023-03-02 Pairwise Plans Services, Inc. Thornless and/or prickleless rubus plants
US12134775B2 (en) 2020-02-21 2024-11-05 Pairwise Plants Services, Inc. Resistance to soybean cyst nematode through gene editing
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
US11999946B2 (en) 2020-03-26 2024-06-04 Pairwise Plants Services, Inc. Methods for controlling meristem size for crop improvement
US11882808B2 (en) 2020-03-27 2024-01-30 Pairwise Plants Services, Inc. Methods for improving resistance to soybean rust
WO2021207148A1 (en) 2020-04-06 2021-10-14 Pairwise Plants Services, Inc. Methods and compositions for increasing resistance to ear rot and stem rot disease in maize
US20230212600A1 (en) 2020-04-16 2023-07-06 Pairwise Plants Services, Inc. Methods for controlling meristem size for crop improvement
MX2022013840A (es) * 2020-05-04 2023-02-09 Inhibrx Inc Polipéptidos de unión a pd-1 canina y usos de los mismos.
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
MA59827B1 (fr) 2020-05-26 2024-10-31 Boehringer Ingelheim International Gmbh Anticorps anti-pd-1
BR112022024489A2 (pt) 2020-06-02 2023-01-31 Pairwise Plants Services Inc Métodos para o controle do tamanho do meristema para melhora da cultura agrícola
AR122661A1 (es) 2020-06-17 2022-09-28 Pairwise Plants Services Inc Métodos para el control del tamaño del meristemo para la mejora de cultivos
AU2021300169A1 (en) 2020-06-30 2023-02-02 Pairwise Plants Services, Inc. Compositions, systems, and methods for base diversification
CA3192195A1 (en) 2020-08-28 2022-03-03 Pairwise Plants Services, Inc. Engineered proteins and methods of use thereof
MX2023005150A (es) 2020-11-06 2023-05-26 Pairwise Plants Services Inc Composiciones y metodos para el reemplazo de alelos con adn codificado por arn.
EP4291641A1 (en) 2021-02-11 2023-12-20 Pairwise Plants Services, Inc. Methods and compositions for modifying cytokinin oxidase levels in plants
CN117203227A (zh) 2021-02-25 2023-12-08 成对植物服务股份有限公司 用于修饰植物中根结构的方法和组合物
CN113189078B (zh) * 2021-03-04 2024-04-16 吉林大学 一种靶向药物的高通量筛选方法
KR20230156079A (ko) 2021-03-09 2023-11-13 젠코어 인코포레이티드 Cd3과 cldn6에 결합하는 이종이량체 항체
WO2022265905A2 (en) 2021-06-14 2022-12-22 Pairwise Plants Services, Inc. Reporter constructs, compositions comprising the same, and methods of use thereof
AR126172A1 (es) 2021-06-17 2023-09-27 Pairwise Plants Services Inc Modificación de factores de transcripción de la familia de factores reguladores del crecimiento en soja
UY39827A (es) 2021-06-24 2023-01-31 Pairwise Plants Services Inc Modificación de genes de ubiquitina ligasa e3 hect para mejorar los rasgos de rendimiento
CN117794358A (zh) 2021-07-01 2024-03-29 成对植物服务股份有限公司 用于增强根系发育的方法和组合物
CN113702351B (zh) * 2021-07-14 2024-08-20 吉林大学 一种对天然药物产物进行筛选和垂钓的方法
WO2023019188A1 (en) 2021-08-12 2023-02-16 Pairwise Plants Services, Inc. Modification of brassinosteroid receptor genes to improve yield traits
PY2270221A (es) 2021-08-17 2023-03-20 Pairwise Plants Services Inc Métodos y composiciones para modificar genes de histidina quinasa receptores de citoquinina en plantas
MX2024002276A (es) 2021-08-30 2024-03-07 Pairwise Plants Services Inc Modificacion de genes de peptidasa de union a ubiquitinaen plantas para mejorar rasgos de rendimiento.
AR126938A1 (es) 2021-09-02 2023-11-29 Pairwise Plants Services Inc Métodos y composiciones para mejorar la arquitectura de las plantas y los rasgos de rendimiento
US20230266293A1 (en) 2021-09-21 2023-08-24 Pairwise Plants Services, Inc. Color-based and/or visual methods for identifying the presence of a transgene and compositions and constructs relating to the same
US12540332B2 (en) 2021-09-21 2026-02-03 Pairwise Plants Services, Inc. Methods and compositions for reducing pod shatter in canola
AR127236A1 (es) 2021-10-04 2024-01-03 Pairwise Plants Services Inc Métodos para mejorar la fertilidad de la flor y el rendimiento de semillas
EP4413022A2 (en) 2021-10-07 2024-08-14 Pairwise Plants Services, Inc. Methods for improving floret fertility and seed yield
AR127904A1 (es) 2021-12-09 2024-03-06 Pairwise Plants Services Inc Métodos para mejorar la fertilidad de floretes y el rendimiento de semillas
WO2023114750A1 (en) 2021-12-13 2023-06-22 Pairwise Plants Services, Inc. Model editing systems and methods relating to the same
WO2023133440A1 (en) 2022-01-06 2023-07-13 Pairwise Plants Services, Inc. Methods and compositions for trichome removal
JP2025504020A (ja) 2022-01-28 2025-02-06 ジョージアミューン・インコーポレイテッド Ｐｄ－１アゴニストであるプログラム細胞死タンパク質１に対する抗体
AR128372A1 (es) 2022-01-31 2024-04-24 Pairwise Plants Services Inc Supresión de la respuesta de evitación de la sombra en las plantas
US20230383271A1 (en) 2022-02-28 2023-11-30 Pairwise Plants Services, Inc. Engineered proteins and methods of use thereof
PY2314419A (es) 2022-03-02 2023-09-25 Pairwise Plants Services Inc Modificación de genes del receptor de brasinoesteroides para mejorar rasgos de rendimiento
CN115015536A (zh) * 2022-03-30 2022-09-06 邹灵龙 一种即时检测pd-1抗体药浓度的试纸条和试剂盒
US20260043040A1 (en) 2022-03-31 2026-02-12 Pairwise Plants Services, Inc. Early flowering rosaceae plants with improved characteristics
AU2023251095A1 (en) 2022-04-07 2024-10-17 Monsanto Technology Llc Methods and compositions for improving resistance to fusarium head blight
CN119278208A (zh) 2022-04-21 2025-01-07 成对植物服务股份有限公司 用于改善产量性状的方法和组合物
PY2331827A (es) 2022-05-02 2023-11-08 Pairwise Plants Services Inc Métodos y composiciones para mejorar el rendimiento y la resistencia a enfermedades
UY40255A (es) 2022-05-05 2023-11-15 Pairwise Plants Services Inc Métodos y composiciones para modificar la arquitectur radicular y/o mejorar los rangos de rendimient
UY40326A (es) 2022-06-27 2023-12-29 Pairwise Plants Services Inc Métodos y composiciones para modificar el escape a la sombra en plantas
CA3259677A1 (en) 2022-06-29 2024-01-04 Pairwise Plants Services, Inc. METHODS AND COMPOSITIONS FOR REGULATING MERISTEMUM SIZE TO IMPROVE CROP PRODUCTION
EP4547693A1 (en) 2022-06-29 2025-05-07 Pairwise Plants Services, Inc. Methods and compositions for controlling meristem size for crop improvement
WO2024030984A1 (en) 2022-08-04 2024-02-08 Pairwise Plants Services, Inc. Methods and compositions for improving yield traits
AR130164A1 (es) 2022-08-11 2024-11-13 Pairwise Plants Services Inc Métodos y composiciones para controlar el tamaño del meristema para la mejora de los cultivos
US20240090466A1 (en) 2022-09-08 2024-03-21 Pairwise Plants Services, Inc. Methods and compositions for improving yield characteristics in plants
CN120500534A (zh) 2022-12-16 2025-08-15 成对植物服务股份有限公司 包含Cas12a多肽和内含肽的融合蛋白和其使用方法
WO2024137911A1 (en) 2022-12-21 2024-06-27 Pairwise Plants Services, Inc. Engineered proteins and methods of use thereof
WO2024173622A1 (en) 2023-02-16 2024-08-22 Pairwise Plants Services, Inc. Methods and compositions for modifying shade avoidance in plants
US20240327811A1 (en) 2023-03-01 2024-10-03 Pairwise Plants Services, Inc. Engineered proteins and methods of use thereof
UY40661A (es) 2023-03-02 2024-10-15 Pairwise Plants Services Inc Métodos y composiciones para modificar la evitación de la sombra en plantas
UY40664A (es) 2023-03-09 2024-10-15 Pairwise Plants Services Inc Modificación de genes de la vía de señalización de brasinoesteroide para mejorar rasgos de rendimien
PE20252680A1 (es) 2023-03-30 2025-11-24 Pairwise Plants Services Inc Metodos y composiciones para reducir las espinas o espinillas en plantas
WO2024216028A1 (en) 2023-04-12 2024-10-17 Agenus Inc. Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
EP4709756A1 (en) 2023-05-10 2026-03-18 Regeneron Pharmaceuticals, Inc. Cd20-pd1 binding molecules and methods of use thereof
PY2439028A (es) 2023-05-18 2025-06-18 Monsanto Technology Llc Métodos y composiciones para mejorar las características de rendimiento de las plantas
AR133164A1 (es) 2023-07-18 2025-09-03 Pairwise Plants Services Inc Métodos y composiciones para modificar la arquitectura radicular en plantas
AR133310A1 (es) 2023-07-27 2025-09-17 Pairwise Plants Services Inc Métodos y composiciones para modificar rasgos de rendimiento de las plantas
WO2025064734A1 (en) 2023-09-21 2025-03-27 Pairwise Plants Services, Inc. Early flowering black raspberry plants with improved characteristics
AU2024348958A1 (en) 2023-09-26 2026-04-02 Pairwise Plants Services, Inc. Fusion proteins, compositions comprising the same, and methods of use thereof
US20250129348A1 (en) 2023-10-09 2025-04-24 Pairwise Plants Services, Inc. Circular permutants, compositions comprising the same, and methods of use thereof
WO2025080600A1 (en) 2023-10-11 2025-04-17 Pairwise Plants Services, Inc. Methods and compositions for improving crop yield traits
US20250207154A1 (en) 2023-12-21 2025-06-26 Pairwise Plants Services, Inc. Compositions and methods for rna-encoded dna-replacement of alleles
WO2025178902A1 (en) 2024-02-22 2025-08-28 Pairwise Plants Services, Inc. Methods and compositions for improving yield characteristics in plants
WO2025252857A1 (en) 2024-06-05 2025-12-11 Institut National de la Santé et de la Recherche Médicale Il-15 muteins with ph-dependent binding for il-15ralpha
WO2025252855A1 (en) 2024-06-05 2025-12-11 Institut National de la Santé et de la Recherche Médicale IL-15 MUTEINS WITH PH-DEPENDENT BINDING FOR IL-15Rbeta
US20260009010A1 (en) 2024-07-08 2026-01-08 Pairwise Plants Services, Inc. Methods and compositions for modification of protospacer adjacent motif specificity of cas12a
US12428636B1 (en) 2024-07-08 2025-09-30 Pairwise Plants Services, Inc. Methods and compositions for modification of protospacer adjacent motif specificity of CAS12A
WO2026019870A1 (en) 2024-07-17 2026-01-22 Pairwise Plants Services, Inc. Engineered crispr/cas12a proteins and methods of use thereof
US20260022365A1 (en) 2024-07-17 2026-01-22 Pairwise Plants Services, Inc. Engineered cytidine deaminases
US12297441B1 (en) 2024-09-11 2025-05-13 Pairwise Plants Services, Inc. Methods and compositions for modifying endocarp structure in Rubus plants
US20260103720A1 (en) 2024-10-15 2026-04-16 Pairwise Plants Services, Inc. Methods for high density planting of rubus plants
US20260117237A1 (en) 2024-10-30 2026-04-30 Pairwise Plants Services, Inc. Engineered proteins and methods of use thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
EP0347425B1 (en) 1987-03-02 1995-12-27 Whitehead Institute For Biomedical Research Recombinant mycobacterial vaccine
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
CA2076753A1 (en) 1990-02-26 1991-08-27 Anthony J. Radford Shuttle plasmid for escherichia coli and mycobacteria
GB9015888D0 (en) 1990-07-19 1990-09-05 Smithkline Biolog Vectors
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0587775A4 (en) 1991-06-06 1994-11-02 Medimmune Inc INDUCTION OF THE CTL RESPONSE BY FOREIGN ANTIGENS EXPRESSED IN MYCOBACTERIES.
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
JP3454275B2 (ja) 1992-06-05 2003-10-06 佑 本庶 プログラムされた細胞死に関連した新規なポリペプチドおよびそれをコードするｄｎａ
WO1994028933A1 (en) 1993-06-04 1994-12-22 New York University Bispecific human monoclonal antibodies specific for human immunodeficiency virus
JPH07291996A (ja) 1994-03-01 1995-11-07 Yuu Honshiyo ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
US20040241745A1 (en) 2001-07-31 2004-12-02 Tasuku Honjo Substance specific to pd-1
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
WO2004056875A1 (en) * 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
JP2007524348A (ja) 2003-01-07 2007-08-30 ダイアックス、コープ クニッツドメインライブラリー
WO2004072286A1 (ja) 2003-01-23 2004-08-26 Ono Pharmaceutical Co., Ltd. ヒトｐｄ−１に対し特異性を有する物質
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
KR101510065B1 (ko) 2005-06-08 2015-04-07 다나-파버 캔서 인스티튜트 인크. 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
CA2947292C (en) 2006-12-27 2019-07-23 Emory University Compositions and methods for the treatment of infections and tumors
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
TW201007669A (en) 2008-08-01 2010-02-16 Integrated Solutions Technology Inc A display driving device and the driving method thereof
JP5794917B2 (ja) * 2008-09-12 2015-10-14 アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ Ｐｄ−１特異抗体およびその使用
CA2736829C (en) 2008-09-12 2018-02-27 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
PL2342226T3 (pl) 2008-09-26 2017-01-31 Dana-Farber Cancer Institute, Inc. Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
CA2790134A1 (en) 2010-02-16 2011-08-25 Valorisation-Recherche, Limited Partnership Pd-1 modulation and uses thereof for modulating hiv replication
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
EP2545078A1 (en) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1 antibody
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
CN103261217B (zh) 2010-11-11 2017-04-26 港大科桥有限公司 可溶性 pd‑1变体、融合构建体及其用途
MX341076B (es) 2011-03-31 2016-08-04 Merck Sharp & Dohme Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
SI2699264T1 (en) 2011-04-20 2018-08-31 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
US9090994B2 (en) 2011-06-08 2015-07-28 Nanjingjinsirui Science & Technology Biology Corp. Antibody humanization by framework assembly
EP2739358B1 (en) * 2011-08-01 2018-11-28 F.Hoffmann-La Roche Ag Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
US20130071403A1 (en) 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
US20150037346A1 (en) * 2012-02-23 2015-02-05 Sloan-Kettering Institute For Cancer Research Prediction of Responsiveness to Treatment with Immunomodulatory Therapeutics and Method of Monitoring Abscopal Effects During Such Treatment
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
LT2904011T (lt) 2012-10-02 2017-11-10 Bristol-Myers Squibb Company Anti-kir antikūnų ir anti-pd-1 antikūnų derinys, akirtas vėžio gydymui
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−１（ｐｄ−１）に対する抗体
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
LT3702373T (lt) * 2013-09-13 2022-11-10 Beigene Switzerland Gmbh Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
US9982052B2 (en) * 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
CA2957258C (en) * 2014-08-05 2023-11-07 MabQuest SA Immunological reagents
DK3237446T3 (en) 2014-12-22 2021-07-26 Pd 1 Acquisition Group Llc Anti-PD-1-antistoffer
US11214617B2 (en) * 2016-01-22 2022-01-04 MabQuest SA Immunological reagents
ES3034233T3 (en) * 2016-01-22 2025-08-14 MabQuest SA Non-blocking pd1 specific antibodies

Also Published As

Publication number Publication date
WO2016020856A3 (en) 2016-03-31
US20190106493A1 (en) 2019-04-11
WO2016020856A2 (en) 2016-02-11
KR20170069996A (ko) 2017-06-21
CA2957258C (en) 2023-11-07
CN107074947A (zh) 2017-08-18
CA2957258A1 (en) 2016-02-11
EP3177644B1 (en) 2020-10-07
PT3177644T (pt) 2021-01-13
AU2015298356A1 (en) 2017-02-16
PL3177644T3 (pl) 2021-06-14
DK3177644T3 (da) 2021-01-11
AU2015298356B2 (en) 2020-11-19
US9982053B2 (en) 2018-05-29
KR102357893B1 (ko) 2022-02-04
US11130807B2 (en) 2021-09-28
CN107074947B (zh) 2021-04-09
ES2847311T3 (es) 2021-08-02
US20220169733A1 (en) 2022-06-02
US20170226210A1 (en) 2017-08-10
JP2017531028A (ja) 2017-10-19
SG11201700672YA (en) 2017-02-27
EP3177644A2 (en) 2017-06-14

Similar Documents

Publication Publication Date Title
US20220169733A1 (en) Immunological Reagents
JP7089474B2 (ja) 免疫学的試薬
US9982052B2 (en) Immunological reagents
JP7374765B2 (ja) 抗ｄｋｋ－１抗体を使用して癌を治療するためのバイオマーカーとしてのベータ－カテニンの使用
US10730933B2 (en) HIV binding agents
US20220259315A1 (en) Immunological Reagents
WO2016077720A1 (en) Binding agents and uses thereof
WO2020012435A1 (en) Hiv binding agents
CA3012075C (en) Immunological reagents
JP7678790B2 (ja) Ｈｉｖ結合剤
HK40042823A (en) Anti-cd73 antibodies and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180806

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20180806

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20180823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180912

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181211

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190327

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191018

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191204

R150 Certificate of patent or registration of utility model

Ref document number: 6629321

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250